EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control

Emmanuel Ifeanyi Obeagu iD

Cancer Reports · 2026-06 · 9 (6)

DOI: 10.1002/cnr2.70602 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Reports, online erschienen am 10.06.2026. Verfasst von Emmanuel Ifeanyi Obeagu. Beteiligte Einrichtung: Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe. Hauptthemen laut MEDLINE: Immunotherapy, Neoplasms. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hematologic disorders, including sickle cell disease, anemias, hemoglobinopathies, leukemias, lymphomas, and bleeding disorders, constitute a substantial and growing burden of morbidity and mortality across Africa. Structural health system constraints—limited diagnostic capacity, shortages of trained hematology specialists, fragmented blood transfusion services, and inequitable access to essential medicines—continue to drive delayed diagnosis, suboptimal treatment, and poor outcomes. Despite these challenges, recent years have witnessed important advances in laboratory strengthening, point‐of‐care diagnostics, access to targeted therapies, and innovative service delivery models. This narrative review synthesizes current evidence on diagnostic and therapeutic gaps in hematology care in Africa and examines emerging strategies aimed at strengthening equitable, sustainable, and context‐appropriate care. Recent Findings Recent initiatives demonstrate measurable progress in several domains. Expansion of point‐of‐care testing and regional laboratory networks has improved early diagnosis of sickle cell disease and hematologic malignancies in countries such as Kenya, Uganda, and Rwanda. Access to essential therapies, including hydroxyurea for sickle cell disease and tyrosine kinase inhibitors for chronic myeloid leukemia, has improved through national insurance schemes and international partnerships in settings such as Ghana and Nigeria, although coverage remains uneven. Innovations in blood transfusion services, including drone‐assisted delivery in Rwanda and strengthened voluntary donation programs in Kenya and Nigeria, have reduced delays in emergency transfusion for severe anemia. Capacity‐building initiatives supported by international collaborations and professional societies have expanded continuing medical education, teleconsultation, and subspecialty training; however, workforce shortages, supply chain vulnerabilities, and financial barriers persist.

Conclusion

Transforming hematology care in Africa requires coordinated, system‐level strategies that integrate diagnostic strengthening, equitable access to essential therapies, resilient blood transfusion services, workforce development, and digital health innovations. While country‐level experiences demonstrate that targeted investments and international collaborations can yield tangible improvements, sustainable progress will depend on stronger health system financing, regional manufacturing and procurement mechanisms, regulatory support, and context‐sensitive implementation research. A deliberate shift from fragmented, disease‐specific interventions toward integrated, patient‐centered hematology care frameworks is essential to reduce preventable morbidity and mortality and to advance equitable cancer and blood disorder outcomes across the continent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyNeoplasmsHumansHealth Services AccessibilityAfrica

Stichwörter der Autor:innen

adaptive resistancemulti‐dimensional immunityprecision immunotherapysynthetic biologytumor microenvironment reprogramming

Autor:innen und Institutionen

  • Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe.
  • Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Emmanuel Ifeanyi Obeagu

Zitieren

APA

Obeagu, E. I. (2026). Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control. Cancer Reports, 9(6). https://doi.org/10.1002/cnr2.70602

Vancouver

Obeagu EI. Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control. Cancer Reports. 2026;9(6). doi:10.1002/cnr2.70602

BibTeX
@article{Obeagu2026,
  author = {Obeagu, Emmanuel Ifeanyi},
  title = {Immunotherapy 3.0: Breakthroughs Steering the Next Generation of Cancer Control},
  journal = {Cancer Reports},
  year = {2026},
  volume = {9},
  number = {6},
  doi = {10.1002/cnr2.70602}
}
Kostenlos starten →